CAJ | 학술논문

2014年6月美国胃肠病学会（ ACG）发布了全球首个关于药物性肝损伤（ DILI）的临床指南：“特异质型药物性肝损伤的诊断和管理”，其内容涵盖了特异质型DILI（ IDILI）的危险因素、诊断、鉴别诊断和治疗等各方面，同时对草药和膳食补充剂（ HDS）引起的DILI和慢性肝病患者的DILI问题进行了专门的讨论。指南对规范DILI的临床诊断和治疗具有重要价值，为IDILI患者提供了最佳管理建议。但目前DILI领域研究的证据质量较弱，临床医师应在指南框架指导下，充分考虑患者可能的个体化差异，作出最佳临床决策。
2014년6월미국위장병학회（ ACG）발포료전구수개관우약물성간손상（ DILI）적림상지남：“특이질형약물성간손상적진단화관리”，기내용함개료특이질형DILI（ IDILI）적위험인소、진단、감별진단화치료등각방면，동시대초약화선식보충제（ HDS）인기적DILI화만성간병환자적DILI문제진행료전문적토론。지남대규범DILI적림상진단화치료구유중요개치，위IDILI환자제공료최가관리건의。단목전DILI영역연구적증거질량교약，림상의사응재지남광가지도하，충분고필환자가능적개체화차이，작출최가림상결책。
The American College of Gastroenterology( ACG)released the first clinical guideline for drug-induced liver injury( DILI)in June,2014:the diagnosis and management of idiosyncratic drug-induced liver injury( IDILI), which includes all aspects of IDILI,such as risk factors,diagnosis,differential diagnosis and treatment. The guideline discusses especially the issues on herbal and dietary supplements( HDS)induced liver injury and DILI in patients with chronic liver disease. The guideline is of great value for standardizing the clinical diagnosis and treatment,providing the best recommendations for management of the patients with DILI. Since the evidence of research in the field of DILI is relatively weak at this moment,the clinicians should consider the possible individual difference of the patients under the frame of guideline for making the best clinical decision.